Online Registry Improves Clinical Research Study Participation
LOS ANGELES (July 13, 2015) - Research for Her™, Cedars-Sinai's groundbreaking online registry that matches women with research studies and clinical trials, enrolled study participants more quickly when compared with traditional paper-based registries, according to new research published in the journal Gynecologic Oncology.
Historically, fewer women have participated in clinical research and only 3 to 5 percent of patients nationally enroll in trials.
"Research for Her is committed to changing these statistics and improving patient lives," saidB.J. Rimel, MD, co-principal investigator of Research for Her, part of the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, and first author of the study.
A total of 322 women were enrolled in the Cedars-Sinai Research for Her registry over a 14-month period - a 4.3 fold increase over the paper-based registry. Of these 322 women, 263 were matched to at least one study and of those, 39 eligible individuals went on to enroll. The enrollment process increased in speed by 27 percent.
The Research for Her registry also spurred a 50 percent increase in enrollments for the Gilda Radner Hereditary Cancer Program, part of the Women's Cancer Program at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in 2014. Founded in 1991, the Gilda Radner program consists of several research studies for women at higher risk for breast and ovarian cancer.
Research for Her, created in 2013, is currently open to all women over the age of 18 with or without a prior history of cancer. It soon will expand to also enroll and link men to available clinical trials or research studies at Cedars-Sinai.
"The early successes of Research for Her are encouraging," said Steven Piantadosi, MD, PhD, director of the Samuel Oschin Comprehensive Cancer Institute and the Phase One Foundation Chair. "We are eager to continue fostering the program's growth and potential, while bolstering patient lives."
Next steps also include identifying innovative methods to capture complex data from patients - such as molecular tumor profiling - to further decrease the time to enrollment for studies and provide more comprehensive prescreening for patients.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
